Urinary Tract
Infection (UTI) Drugs Market Information, by Drug Class (Quinolones,
Aminoglycosides, β-lactam, Azoles and others), by Clinical Indications
(Urethritis, Cystitis, Pyelonephritis) and End User (Hospitals and Self-administered)
- Forecast to 2022
Market Highlights
:
UTI drugs are used
for the treatment of Urinary
Tract Infection(UTI) Market caused by bacterial or fungal infections. World
Health Organization (WHO) estimates that approximately 50 % of women have UTI
at some point in their lives resulting in more than $1 million hospitalizations
per year. WHO estimates the cost of UTI infections to be annually greater than
$1 billion. It has further been stated that chances of boys being diagnosed
with UTI is 1% while chances of girls being diagnosed with UTI is 3 to 8%. The
Middle East and Africa UTI drugs market is growing due to factors such as
catheter associated UTI, hospital borne infections (nosocomial infections),
child birth, old age, obesity, growing health awareness especially about women
health etc. On the other hand market constraints includes excellent efficacy of
present antibiotics specially quinolones, growing drug resistance, unmet
clinical needs, increasing incidence of chronic diseases etc. However, the rise
of drug resistance has created the need for novel acting antibiotic. The future
of UTI treatment seems to be development of biologics with greater market development
especially with respect to poorly growing African market. The loss of patents,
weakening developed pipelines and poor expenditure on health in African region
had further constrained the market growth.
The Middle East and
Africa UTI drugs market has been segmented into drug class which includes
quinolones, aminoglycosides, β-lactam, azoles and others. Among all these drug
classes quinolones have the largest market value due to their broad variety and
excellent efficacy. The share of aminoglycosides have been reduced by a small
margin as this drug is resistance. Thus the current trend in UTI treatment is
combined drug regimen. The market threat includes a form of substandard,
counterfeit and spurious drugs have emerged. However it has to be noted that a
huge unmet need exists for these drugs in the Middle East and African region.
Access Report
Details @ https://www.marketresearchfuture.com/reports/mea-uti-drugs-market-2540
Key Players:
Major participants
of this market are: Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche
Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd. and others.
Middle East and
Africa UTI Drugs market:
The Middle East and
Africa UTI drugs market has been evaluated to be growing market and is expected
that the market will grow moderately in the future. The Middle East and Africa
UTI drugs market is expected to grow with the CAGR of 4.35% during the forecast
period. The growth will primary be led by unmet medical needs and rising
incomes of the population.
Regional
Analysis:
Depending on
geographic region, UTI drugs market is segmented into following countries: UAE,
Egypt, Saudi Arabia, Kuwait, Qatar and Oman; UAE is the largest market followed
by Egypt. However the future market will be led by poorly developed parts of
Africa due to large unmet needs.
Market
Segmentation:
Middle East and
African UTI drugs market has been segmented on the basis of drug class which
comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the
basis of clinical Indications the market is segmented into urethritis, cystitis
and pyelonephritis. On the basis of end users, market is segmented into
hospitals and self-administered.
No comments:
Post a Comment